NeuroVia, Inc. is committed to addressing unmet medical needs in neurological diseases with the primary goal to arrest the onset of devastating neurological deficits associated with X-ALD.
|
Date |
Amount |
Type |
Investors |
Valuation |
|---|---|---|---|---|
| 07/20/17 | $14,000,000 | Series A |
BioMed Ventures Novartis Venture Funds  Sanofi-Genzyme BioVentures | undisclosed |
